NATEVBA
(vevasumab)

Natevba (vevasumab):
Precision targeting in XA+ Non-Hodgkin’s lymphoma



Current treatments do not effectively target malignant cells and therefore have high toxicity[1]

Unlike in other types of NHL, monoclonal antibody treatments show poor efficacy in XA+ subtypes and are generally not used[1]

Chemotherapy is the standard of care, but has limited efficacy and high toxicity[1]



1 in 4 XA+ NHL patients discontinue chemotherapy due to adverse events.[1]

NHL = non-Hodgkin's lymphoma; XA + = X-antigen-positive.

1. Mcguire T et al. Cancer Therapy Review 2018;12 (4):469–470.

Natevba offers clinically meaningful improvements in QoL[1]

Natevba improved or maintained QoL for the duration of treatment in all five EuroQoL domains:

Mobility | Self-care | Usual activity | Pain | Depression

1. Vincent A et al. Cancer Therapy and Management 2020;22 (1):87–88.

QoL = quality of life

NATEVBA

(vevasumab)

Natevba is an innovative new treatment targeting X-antigen[1]

Natevba is indicated for the first-line treatment of X-antigen positive (XA+) non-Hodgkin's lymphoma[1]

1. Natevba (vevasumab) Summary of Product Characteristics

With Natevba, precision targeting ensures minimal toxicity

Natevba has a more favourable tolerability profile than chemotherapy, with a lower incidence of Grade 3–4 adverse events[1,2]

Natevba has a low incidence of haematological adverse events, including neutropenia[1]

Adverse events are generally reversible with appropriate dose adjustments[1]

1. Vincent A et al. Cancer Therapy and Management 2020;22 (1):87–88.
2. Natevba (vevasumab) Summary of Product Characteristics.

With Natevba, precision targeting delivers exceptional results[1]

Over 2 years median progression-free survival[1]

Meaningful improvements in quality of life[1]

Over 80% response rate[1]

PFS= Progression-free survival QoL = Quality of Life

1. Vincent A et al. Cancer Therapy and Management 2020;22 (1):87–88.

Natevba delivers over two years median PFS[1]



1. Vincent A et al. Cancer Therapy and Management 2020;22 (1):87–88.

CI = confidence interval HR = hazard ratio PFS = progression-free survival

Over 80% of patients respond to Natevba[1]



1. Vincent A et al. Cancer Therapy and Management 2020;22 (1):87–88.

CI = confidence interval CR = complete response ORR = objective response rate

Natevba is the only treatment to target X-antigen, a highly specific marker of malignant lymphocytes[1]



In X-antigen-positive (XA+) non-Hodgkin's lymphoma (NHL), malignant lymphocytes are identifiable by a unique surface marker known as X-antigen.

Natevba is an antibody-drug conjugate with three parts:

- Antibody specific to X-antigen
- Linker
- Cytotoxic agent

Natevba recognizes X-antigen on malignant lymphocytes and binds strongly. Binding triggers uptake of the drug into the cell. Inside the cell, the linker is cleaved, releasing the cytotoxic agent. This induces apoptotic cell death.

Natevba's manageable dosing schedule lets patients get on with life[1]

Natevba has a convenient 4-weekly infusion schedule[1]

The recommended dose is 1 .8 mg/ kg administered as an intravenous infusion over 30 minutes every 4 weeks

Natevba is indicated as monotherapy, freeing patients from the burden of chemotherapy[1]

1. Natevba (vevasumab) Summary of Product Characteristics.

X-antigen positive (XA+) non-Hodgkin's lymphoma (NHL) is a particularly aggressive subtype of NHL, with a poor prognosis

Worldwide, over half a million people are diagnosed with NHL per year[1]

XA+ NHL is an aggressive subtype with rapid progression and a low survival rate[1]

1. Mcguire T et al. Cancer Therapy Review 2018;12 (4):469–470.

Natevba:

Precision targeting in XA+ NHL

An innovative new treatment targeting X-antigen[1]

Exceptional clinically proven results[2]

Minimal toxicity compared to chemo[2]

NHL = non-Hodgkin’ s lymphoma; XA+ = X-antigen-positive.

1. Natevba (vevasumab) Summary of Product Characteristics.
2. Vincent A et al. Cancer Therapy and Management 2020;22 (1):87–88.

Natevba Efficacy

Local Event

Location: Elite Spire Hotel

Date: 15th of March 2024

Do you want to attend?

Register | here |

NATEVBA
(vevasumab)